A number of companies are planning to jump into the lucrative breast cancer genetic testing market and are promising lower prices. But they face legal battles with the company that previously was the sole provider of these tests.
Madison, N.J.-based Quest Diagnostics, one of the largest clinical laboratories in the U.S., started offering BRCA testing last week. It is the largest company to begin offering genetic tests that identify the BRCA1 and BRCA2 genes—which are associated with higher risks for hereditary breast and ovarian cancers—since the U.S. Supreme Court in June ruled that Myriad Genetics' patents for naturally occurring DNA were invalid. Until the ruling, Salt Lake City-based Myriad Genetics was the sole provider of BRCA testing in the U.S.